EP4363406
NLRP3 BÓLGUEYÐANDI HEMLAR
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
1.7.2022EP published:
10.9.2025EP application number:
22744149.0
EP translation filed:
15.12.2025Grant published:
14.1.2026EPO information:
European Patent Register
Max expiry date:
30.6.2042Expiry date:
30.6.2026
Title in English:
NLRP3 INFLAMMASOME INHIBITORSLanguage of the patent:
English
Timeline
Today
1.7.2022EP application
10.9.2025EP Publication
15.12.2025Translation submitted
14.1.2026Registration published
30.6.2026Expires
Owner
Name:
Astrazeneca ABAddress:
151 85 Södertälje, SE
Name:
Mitsubishi Tanabe Pharma CorporationAddress:
3-2-10, Dosho-machi, Chuo-ku,, Osaka-shi, Osaka 541-8505, JP
Inventor
Name:
JOHANSSON, Lars Anders MikaelAddress:
151 Södertälje, SE
Name:
GRADÉN, HenrikAddress:
151 Södertälje, SE
Name:
BERGONZINI, GiuliaAddress:
151 Södertälje, SE
Name:
SUGAMA, HiroshiAddress:
Osaka-shi, Osaka 541-8505, JP
Name:
MATSUMURA, TakehikoAddress:
Osaka-shi, Osaka 541-8505, JP
Agent
Name:
Novagraaf BrevetsAddress:
Bâtiment O2, 2 rue Sarah Bernhardt CS90017, FR
Priority
Number:
202163217970 PDate:
2.7.2021Country:
US
Classification
Categories:
C07D 237/34, C07D 471/04